South America Insulin Infusion Pump Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

South America Insulin Infusion Pump Market Trends and Insights

Rising Type 1 Diabetes Diagnosis and Survival

Improved diagnosis rates and longer life expectancy among people with type 1 diabetes are expanding the potential user base for insulin infusion pumps in South America. Brazil had an estimated 517,290 people living with type 1 diabetes, while Argentina had 86,977 people with the condition in 2025.^{[1]International Diabetes Federation, “IDF Diabetes Atlas, 11th Edition,” International Diabetes Federation, diabetesatlas.org} In Brazil, childhood type 1 diabetes incidence increased from 10.4 to 12.8 per 100,000 population between the mid-1980s and 2015. Insulin pump use reached only 3.5% in the BrazDiab1SG cohort, indicating substantial adoption potential. Expanded coverage in Argentina also supported access to pump therapy for eligible patients.

Increasing Adoption of Automated Insulin Delivery

Automated insulin delivery is moving the South America insulin infusion pump market toward integrated pump-and-sensor treatment. A 2025 study of 174 users found that the share meeting all consensus glycemic targets increased from 9.7% at baseline to 52% after 12 months. In July 2025, MiniMed 780G received an expanded CE Mark indication for children aged 2 years and older, pregnant women, and adults with insulin-requiring type 2 diabetes.^{[2]Gregory A. Olveira et al., “Global Type 1 Diabetes Prevalence, Incidence, and Mortality Estimates 2025,” Diabetes Research and Clinical Practice, doi.org} The United States Food and Drug Administration approved the system for insulin-requiring adults with type 2 diabetes in September 2025. Argentina had a 14% age-standardized diabetes prevalence, while Colombia had 3 million adults living with diabetes.

Growth of Connected Pumps and CGM Integration

Connected glucose monitoring is becoming an essential component of the South America insulin infusion pump market, particularly among urban private-care users. A 2025 regional expert consensus addressed the accuracy, interoperability, and post-market monitoring of continuous glucose monitors used in automated insulin delivery systems.^{[3]Bruno Resende et al., “Type 1 Diabetes in Brazil: A Narrative Overview of the Brazilian Type 1 Diabetes Study Group,” Diabetology & Metabolic Syndrome, link.springer.com} Argentina’s Resolution 2091/25 identified Abbott’s FreeStyle Libre as a covered continuous glucose monitoring technology while supporting insulin pump coverage. In Chile, partial reimbursement for continuous glucose monitoring sensors supported connected diabetes care, although broader pump access remained limited.

Judicialization and Individual Patient Access to High-Cost Devices

Judicial access has become a direct demand driver for the South America insulin infusion pump market in Brazil. Some patients sought court orders requiring private insurers to provide pumps not included in the mandatory coverage list. In August 2025, the Superior Tribunal de Justiça held a public hearing on Tema 1316 to assess whether private health plans must cover insulin infusion pump systems. The Brazilian Diabetes Society, the Federal Public Defender’s Office, and the health regulator participated in the discussion. A favorable binding decision could expand access beyond case-by-case litigation for Brazil’s more than 50 million private health plan members.

Unequal Reimbursement and High Out-of-Pocket Costs

Unequal reimbursement coverage limited the South America insulin infusion pump market to a small share of the clinically eligible population. In Brazil, mandatory private insurance did not cover insulin pump systems or consumables, with devices costing up to BRL 30,000 (USD 5,817) and recurring consumables costing BRL 3,000 (USD 581) per month. Chile did not include pump treatment in its Garantías Explícitas en Salud benefit package, while Ley Ricarte Soto covered only 9% of eligible type 1 diabetes patients in the cited registry data. Pressure on Peru’s basic insulin supplies in early 2026 indicated continued challenges in accessing premium devices.

Import Dependence, Currency Volatility, and Device Affordability

The South America insulin infusion pump market relied on imported hardware and precision consumables. In Argentina, currency depreciation and fragmented exchange rates increased device costs for distributors and patients. In Brazil, Class III pump devices required technical review and good manufacturing practice compliance before commercial entry, increasing timelines and costs. In January 2026, Insulet announced plans for a diabetes care manufacturing facility in Costa Rica, with an investment exceeding USD 200 million, which could improve consumable supply and lead times for South American distributors over time.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Component: Insulin Pump Devices Anchor Hardware Revenue

Insulin pump devices accounted for 65.12% of the South America insulin infusion pump market size in 2025, reflecting high spending on first-time hardware placements in a market with a limited installed base. Pump penetration among people with type 1 diabetes in Brazil remained below 5%. Consequently, replacement demand did not develop at the same scale as new hardware demand, supporting higher device revenue and average selling prices. Infusion sets represented the second-largest component, as clinical practice required replacement every 2–3 days.

Reservoirs are forecast to be the fastest-growing component at a 6.89% CAGR during 2026–2031. Each new automated insulin delivery system creates recurring reservoir demand, while closed-loop systems adjust basal insulin and correction doses more frequently than manual therapy. This increases insulin throughput and reservoir turnover, enabling reservoir sales to grow faster than initial device placements. Brazil’s quality and biocompatibility requirements for Class III insulin-contacting components continue to favor established suppliers, although new entrants are testing incumbent pricing.

By Pump Type: Patch Pumps Set the Competitive Pace

Patch pumps are forecast to grow at a 7.22% CAGR during 2026–2031 in the South America insulin infusion pump market. Their tubeless design eliminates the catheter-management burden associated with tethered systems and supports discreet use during work, sports, and daily activities. Insulet’s Omnipod has strong recognition in the regional tubeless category. Medtrum’s Nano pump received Brazilian registration in October 2025, while Uruguay’s Fondo Nacional de Recursos updated its 2025 protocol to include Nano TouchCare for eligible patients aged 2–21.

Tethered pumps retain an important installed base in Brazil and Argentina. Medtronic’s MiniMed 780G remains well established among endocrinologists treating complex type 1 diabetes, supported by expanded CE Mark indications for young children, pregnant women, and adults with insulin-requiring type 2 diabetes. These patient groups often require close clinical oversight, supporting tethered pump use in specialty practice. Chile’s March 2026 regulatory reform introduced a risk-based registration process for all pump types, with a 24–36-month transition period that may affect new device launches.

By Patient Type: Type-2 Diabetes Drives Volume While Type-1 Diabetes Anchors Clinical Need

Type 2 diabetes accounted for 68.56% of the South America insulin infusion pump market size in 2025. This share reflected the substantially larger population with type 2 diabetes rather than widespread automated system adoption in this group. Brazil had 17 million adults living with diabetes, most of whom had type 2 diabetes, while Argentina’s type 2 diabetes-to-type 1 diabetes ratio exceeded 40:1. The September 2025 United States approval of MiniMed 780G for insulin-requiring adults with type 2 diabetes provided additional support for automated delivery in this population.

Type 1 diabetes remains the patient group with the strongest clinical need for pump therapy. The BrazDiab1SG cohort found that only 11.6–17.9% of adults with type 1 diabetes achieved optimal glucose control with multiple daily injections. Argentina’s Resolution 2091/25 expanded consumable provision for existing pump users, a population heavily weighted toward type 1 diabetes. Brazil’s pending coverage decision could improve access for patients who currently rely on litigation, while expanded specialist care in Colombia and Chile could improve patient identification and treatment.

By End User: Hospitals Lead Today While Homecare Gains Momentum

Hospitals and clinics held 54.34% of the South American insulin infusion pump market in 2025. Demand is concentrated in major private networks in São Paulo, Rio de Janeiro, Buenos Aires, Bogotá, and Santiago, where endocrinology teams manage pump procurement and initiation. Insurer authorization requirements in Brazil and Colombia also reinforce supervised institutional starts. Colombia’s healthcare system allocated COP 114.8 trillion to health spending in 2026, with specialty-device purchasing increasingly managed through hospital network contracts.

Homecare is projected to grow at a 7.67% CAGR during 2026–2031. Closed-loop systems require less daily manual intervention after patient configuration and training, while remote monitoring enables specialists in major cities to oversee patients remotely. These factors reduce the need for hospital-based initiation and help insurers manage treatment costs. Medtrum’s Nano system adjusts basal and correction doses after configuration, increasing the importance of direct consumable distribution, last-mile delivery, and cold-chain capabilities.

Geography Analysis

Brazil held 52.56% of the South American insulin infusion pump market in 2025. Its position reflected its population size and developed a private supplementary healthcare system, which covered more than 50 million people. Annual diabetes-related healthcare expenditure reached USD 45.1 billion. MiniMed 780G is commercially available in Brazil, and Medtrum’s Nano pump received national registration in October 2025. The pending Tema 1316 decision remains significant, as it could shift private coverage from individual litigation to a more consistent entitlement.

Argentina is forecast to expand at a 6.45% CAGR during 2026–2031, making it the region’s fastest-growing geography. Resolution 2091/25 extended mandatory coverage for newer pump models through Obras Sociales and prepaid entities. Argentina had a 14% age-standardized diabetes prevalence and 4.3 million adults living with diabetes. Colombia had a 6–8-month registration route for Class IIb and III devices, while its May 2026 direct-payment reform improved payment predictability for suppliers. Chile had 1.9 million adults living with diabetes and a 12.2% prevalence, and its March 2026 reform introduced a structured Class I–IV registration system for pumps.

Peru remains constrained by limited basic insulin supply security and premium-device access. The suspension of an NPH insulin supplier registration in late 2025 led to emergency procurement of 75,000 NPH insulin units in early 2026, indicating that healthcare priorities remain focused on essential diabetes supplies. Bolivia, Uruguay, Venezuela, Ecuador, and Paraguay make smaller contributions to the market. Uruguay stands apart because its Fondo Nacional de Recursos covers Nano TouchCare patch pumps for eligible patients aged 2–21, providing a clearer access route for pediatric and adolescent users.